Dan Gold, Ph.D., Joins as Chief Executive Officer
MENLO PARK, Calif., Dec. 10 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB), a privately held biotechnology company, announced the completion of a $21 million Series B financing. Prior investor SV Life Sciences (SVLS) led the round followed by co-lead investor Alta Partners. The proceeds from the financing will be used to develop FAB's novel, cell-free protein synthesis technology to produce biologic drugs and vaccines for unmet medical needs. David Mack, Ph.D., Director at Alta Partners has joined Michael Ross, Ph.D., Managing Partner at SVLS, as a member of the Board of Directors.
Cell-free technology was designed to overcome the limitations of cell-based production of proteins that are often subject to degradation, low yields and purification difficulties, or are not therapeutically effective because of structural deficiencies due to poor folding.
FAB's proprietary cell free protein synthesis technology was developed by James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis. Dr. Swartz holds the Leland T. Edwards Professorship in the School of Engineering at Stanford University and is a Professor in the Departments of Bioengineering and Chemical Engineering. He is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. Dr. Swartz serves on the Board of Directors of the company.
FAB also announced that Daniel Gold, Ph.D. has joined the company as
Chief Executive Officer. Dr. Gold has over twenty years of
biopharmaceutical process development and manufacturing experience. He
joins FAB from Human Genome Sciences (HGS) where he was Senior Vice
President, Manufacturing Alliances, and Senior Vice President of
Pharmaceutical Operations. Prior to joining HGS, Dr. Gold was Vice
President, Process Development and Chief Scientific Officer at
|SOURCE Fundamental Applied Biology, Inc.|
Copyright©2007 PR Newswire.
All rights reserved